Regeneron is recruiting for a phase 2 RCT of REGN7544 (an NPR1 antagonist mAb) for POTS. Theyβre seeking 81 patients in Pasadena, CA; Carlsbad, CA; Nashville, TN; and Clearwater, FL clinicaltrials.gov/study/NCT065...
Regeneron is recruiting for a phase 2 RCT of REGN7544 (an NPR1 antagonist mAb) for POTS. Theyβre seeking 81 patients in Pasadena, CA; Carlsbad, CA; Nashville, TN; and Clearwater, FL clinicaltrials.gov/study/NCT065...
Many of the unregulated proteins they found in post-Covid POTS patients have also been found to be unregulated in pre-Covid POTS patients pmc.ncbi.nlm.nih.gov/articles/PMC...
This is deeply shocking and disturbing, the opposite of scientific good practice. As I see it, a group of diehards promoting a discredited treatment (exercise "therapy" for ME/CFS patients) are seeking to stifle medical progress - to protect their reputations. And Cochrane has kowtowed to them. π§΅
1) There is some (cautious) excitement about this new ME/CFS paper that will soon be published.
It replicated abnormalities in B-cells that were found by 2 earlier studies, namely an increase in Immunoglobulin Heavy Variable IGHV3-30.
Important update from the European ME Coalition (EMEC) regarding European funding for ME/CFS π
Visual symptoms in postural tachycardia syndrome
pots-radar.ghost.io/visual-sympt...
Not sure what to make of this (it was a single-blind study).
Press release from Dec. 19: www.biospace.com/press-releas...
Meeting abstract from Dec. 6, in the American Society of Hematologyβs journal Blood: www.sciencedirect.com/science/arti...
Blood Pressure Regulation in PostβCOVID POTS
pots-radar.ghost.io/blood-pressu...
pots-radar.ghost.io/welcome/
Hello, world!
This is POTS Radar π‘
Follow for reviews of the latest research on Postural Orthostatic Tachycardia Syndrome (POTS).